NIH Panels Meet Behind Closed Doors to Award Grants
Published Date: 6/1/2026
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Protection of Trade Secrets and Privacy
The notice states the discussions could disclose confidential trade secrets, commercial property (including patentable material), and personal information tied to grant applications, so meetings are closed to prevent unwarranted invasions of privacy. This legal basis is cited specifically as sections 552b(c)(4) and 552b(c)(6) of Title 5, U.S.C.
Closed NIH Grant Review Meetings
The NIH Center for Scientific Review will hold multiple closed virtual meetings to review and evaluate grant applications on June 23, 2026; June 29, 2026; and June 29–30, 2026. Meetings are closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) and list times such as 8:30 a.m. to 7:00 p.m. and 9:00 a.m. to 6:00 p.m. for specific panels.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
2026-14752, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in August 2026 to review and evaluate important grant and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding to fight antibiotic resistance, support schizophrenia research, and boost medical tech. If you’re involved in these fields, keep an eye on these dates—they could impact future research dollars and projects.
Previous / Next Documents
Previous: 2026-10813, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Next: 2026-10815, Request for Information: Shaping the Future of the Bureau of Transportation Statistics
The Bureau of Transportation Statistics wants your ideas to make their data and tools better for everyone who uses them. They’re looking to fix gaps and keep up with new tech and changes in how we move stuff around. If you have thoughts, send them by July 2, 2026, to help shape the future of transportation info—no money needed, just your voice!